Active	Status	Sponsor type	Region	Phase	Filter
5 Active 9 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Moizerto (difamilast) / Otsuka, Medimetriks
NCT05372653: A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis	Completed	3	41	Japan	OPA-15406, difamilast	Otsuka Pharmaceutical Co., Ltd.	Atopic Dermatitis (AD)	12/22	11/23
NCT05608343: This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)	Completed	3	153	US	Difamilast, Placebo	Acrotech Biopharma Inc.	Atopic Dermatitis	10/23	10/23
NCT05667623: To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD	Recruiting	3	270	RoW	1% OPA-15406 Ointment, 0% OPA-15406 Vehicle	Otsuka Beijing Research Institute	Atopic Dermatitis (AD)	07/24	01/25
NCT05650320: To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients With AD	Recruiting	3	240	RoW	0.3% OPA-15406 Ointment, 1% OPA-15406 Ointment, 0% OPA-15406 vehicle	Otsuka Beijing Research Institute	Atopic Dermatitis (AD)	11/24	05/25
NCT05571943: A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis	Completed	3	542	US	Difamilast	Acrotech Biopharma Inc.	Atopic Dermatitis	07/24	07/24